AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins for the treatment of debilitating medical conditions. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine. AEON Biopharma, Inc. is based in Fort Lauderdale, Florida.